|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RNA interference and cancer therapy显示文摘 | Wang Z Rao DD Senzer N | 2011 | Pharm Res2011，28，12： | 1 |
| 2 | Multi- center phase lI study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck显示文摘 | SOULIERES D SENZER N N VOKES E E | 2004 | J Clin Oncol2004，22，： | 1 |
| 3 | Oral administration of elofarabine daily x5 every 4 weeks in patients with advanced solid tumors in a phase Ⅰ and pharmaeokinetie study显示文摘 | CUNNINGHAM CC NEMUNAITIS J SENZER N | 2004 | Eur J Cancer2004，8，2： | 1 |
| 4 | A phase Ⅰ trial of intravenous infusion of ONYX 015 and enbrel in solid tumor patients显示文摘 | NemunaitisJ Senzer N Sarmiento S | | 0，，11： | 1 |
| 5 | Phase II clinical trial of a granulocyte-macrophage colony- stimulating facors-encoding,second-generation oncolytic herpesvirus in patients with unresetable metastatic melanom显示文摘 | Senzer N N Kaufman H L Amaturda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 6 | Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development 显示文摘 | Rao DD Senzer N Cleary MA | 2009 | Cancer Gene Ther2009，16，11： | 1 |
| 7 | Phase II trial of Belagen- pumatucel -L, a TGF -beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer(NSCLC) patients显示文摘 | Nemunaitis J Nemunaitis M Senzer N | 2009 | Cancer Gene Ther2009，16，： | 1 |
| 8 | Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (MDA-7/IL-24): Biologic outcome in advanced cancer patients 显示文摘 | Tong AW Nemunaitis J Su D Zhang Y Cunningham C Senzer N | 2005 | MolTher2005，11，1： | 1 |
| 9 | Stathmin 1:a novel therapeutic target for anticancer activity显示文摘 | Rana S Maples PB Senzer N | 2008 | Expert Rev Anticancer Ther2008，8，9： | 1 |
| 10 | RNA interference and cancer therapy显示文摘 | Wang Z Rao DD Senzer N | | 0，，12： | 1 |
| 11 | Induction of immune responses and clinical efficacy in a phase Ⅱ trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small cell lung cancer 显示文摘 | BARBE M BENDER J SENZER N | 2008 | J Clin Oncol2008，26，27： | 1 |
| 12 | RNA interference andpersonalized cancer therapy显示文摘 | Rao DD Wang Zhao-hui Senzer N | 2013 | Discov Med2013，15，81： | 1 |
| 13 | TNFerade biologic, an adenovector with radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase 1 study in patients with solid tumors显示文摘 | Senzer N Mani S Rosemurgy A | 2004 | J Clin Oncol2004，22，4： | 1 |
| 14 | Stathmin 1:a novel thempeutic target for anticancer activity显示文摘 | Rana S Maples PB Senzer N | | 0，，09： | 1 |
| 15 | A phase Ⅰ trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients显示文摘 | Nemunaitis J Senzer N Sarmiento S | 2007 | Cancer Gene Ther2007，14，11： | 1 |
| 16 | PhaseⅡ trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients显示文摘 | Nemunaitis J Nemunaitis M Senzer N | 2009 | Cancer Gene Ther2009，16，8： | 1 |
| 17 | Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers 显示文摘 | Cho LC Senzer N Peters GN | 2002 | Am J Surg2002，183，6： | 1 |
| 18 | RNA interfer- ence and personalized cancer therapy 显示文摘 | RAO D D WANG Z SENZER N | 2013 | Discov Med2013，15，81： | 1 |
| 19 | RNA interference and cancer therapy显示文摘 | Wang Z Rao DD Senzer N | 2011 | Pharm Res2011，28，12： | 1 |
| 20 | Phase Ⅱ trial of Belagenpumatucel-L,a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung Cancer (NSCLC) patients显示文摘 | Nemunaitis J Nemunaitis M Senzer N | | 0，，08： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员